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Original Article
IntroductIon
The World Health Organization End Tuberculosis (WHO 
End TB) Strategy, approved by the World Health Assembly 
in 2014, calls for an action driving to an 80% reduction in 
the TB incidence rate and 90% reduction in TB deaths by 
2030 compared with the 2015 ciphers. In this last year, the 
Sustainable Development Goals for 2030 were adopted by 
the United Nations.[1]
According to 2017 WHO report, an estimated 10.4 million 
people fell ill with TB in 2016.[2] The decline rate in TB 
incidence worldwide was only 1.5% from 2014 to 2015.[1] 
Therefore, to reach the first milestones of the End TB Strategy, it 
will be necessary to accelerate the decline to a 4%–5% annually 
by 2020.[1,2] In addition, TB control is mainly threatened among 
other factors by the rise of immunosuppressive conditions in 
the hosts and the appearance of drug‑resistant (DR‑TB) cases 
particularly by the emergence of extensively DR‑TB (XDR‑TB) 
strains.[3‑5] Contributing to worsening this situation, the WHO 
2017 reported 129,689 people starting treatment for DR‑TB, a 
small increase from 125,629 in 2015 but only 22% of the whole 
estimated incidence. Besides, the treatment success remains 
low at only 54% globally.[2]
Abstract
Background: Argentina is considered a country with a middle tuberculosis (TB) incidence. However, according to the last national 
epidemiological report released in 2018, since 2013, the trends are steadily increasing. The aims of this study were to determine the 
drug‑resistance (DR), multi‑DR and extensively DR (MDR/XDR‑TB), and rifampicin resistance (RIF‑R) burden as a part of the local TB 
diagnosis (June 2010–August 2018); to detect the mutations associated to isoniazid (INH) and RIF‑R and their geographical distribution; 
and to analyze the lineage relationship among the genetic patterns of the isolates circulating in the community. Methods: Respiratory and 
extrapulmonary specimens were processed by Ziehl–Neelsen stain and cultured on specific media. Drug‑susceptibility testing of isolates was 
performed by the MGIT 960 and a colorimetric micro‑method. Mutations conferring DR were detected by Genotype and DNA sequencing. 
Results: The study showed a DR‑TB prevalence of approximately 20% of the isolated strains, while M/XDR‑TB‑and particularly RIF‑R‑affected 
more than 5.0% of the total amount of cases. DR geographical distribution revealed isolates carrying mutations in the inhA gene promoter 
region only constrained to three districts where it was also registered two same family relatives’ cases with the infrequent rpoB S522 L/Q 
mutation. The fact that most DR/MDR‑TB isolates were not grouped in genetic clusters suggested that these cases may mostly have occurred 
due to endogenous reactivation rather than recently transmission. Conclusion: According to the obtained results, it would be convenient, in 
highly MDR‑TB suspected individuals, to confirm phenotypically, the INH and RIF susceptibility detected by molecular tests.
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Mycobacterium tuberculosis – the main pathogen of the 
M. tuberculosis complex – can acquire several resistances 
mainly to the first‑line and eventually to second‑line 
anti‑TB antibiotics. Based on the genetic changes in 
the M. tuberculosis genome and with epidemiological 
and clinical purposes, DR‑TB can be classified as 
rifampicin (RIF)‑resistant (RR‑TB); multi‑DR (MDR‑TB), 
caused by strains simultaneously resistant to isoniazid (INH) 
and RIF; and XDR‑TB, caused by MDR strains with the 
additional resistance to a fluoroquinolone (FQ) and an 
injectable second‑line drug.[3,6]
In 2016, there were estimated 600,000 new RR‑TB cases, the 
most effective first‑line anti‑TB drug, being 490,000 of them 
caused by MDR‑TB strains.[2]
In Argentina, a total of 11,560 TB cases were reported to the 
National TB Control Program in 2016, with an incidence 
rate of 26.5/100,000 inhabitants and 6.4% increment 
comparing with 2014.[7,8] During 2015–2016, MDR‑TB 
accounted for 174 cases, 5.3% had not had a previous 
treatment history, while 12 patients accomplished with the 
XDR‑TB criteria.[7,8]
Dr. Cetrángolo Hospital (CH) is a reference center for 
diagnosis and treatment of lung diseases, including TB and 
mycobacterioses for the Northern Sanitary Region of Buenos 
Aires Province (NSRBA). It comprises an area of 9227.13 km2 
with around 4 million inhabitants (calculated population 
density: 433.5 inhabitants/km2).[9]
As Argentina itself, CH has kept DR‑TB surveillance, and 
the prevalence of MDR‑TB cases records for more than 
20 years.[7] In fact, CH has contributed with 27 RR‑TB, 21 
MDR‑TB (21/174, 12.1%) cases, for the above‑mentioned 
2015–2016 period of the national DR surveillance. At 
the same time and also among patients receiving medical 
attention at CH, there were diagnosed 3 XDR‑TB cases in 
no previously treated children between 10 and 14 years 
old (NM personal communication).[7,8] These last figures 
confirm the spreading and transmission of DR bacilli in 
the community.
Therefore, the aims of this study were to determine the 
clinical burden of M/XDR‑TB and RR‑TB as a part of the 
overall TB diagnosis in CH from June 2010 to August 2018; 
to detect the mutations associated to INH and RIF resistance 
and their geographical distribution; and to analyze the lineage 
relationship among the genetic patterns of the isolates that are 
being actively transmitted in this community.
Methods
Clinical and epidemiological information of the cases
During the study (June 2010 to August 2018), the following 
information was collected: age, gender, HIV infection, 
residence district, localization of the disease, HIV coinfection, 
and comorbidities. The cases were referred to the residence 
geographical localization in NSRBA.
Microbiologic diagnostic
Respiratory and extrapulmonary specimens but blood were 
processed by Ziehl–Neelsen stain and cultured on solid 
egg‑based media and the BACTEC MGIT 960™ system. 
Myco‑F‑Lytic BACTEC 9050™ system was used to culture 
blood samples.[10,11]
First‑line drug‑susceptibility testing (DST) was performed by 
the commercial kit SIRE MGIT 960™[12] and the second‑line 
DST by a colorimetric micro‑method (resazurin microassay, 
REMA) that uses resazurin as a vital dye that indicates 
bacterial growth or the absence of it. This method was also 
used to determine the DR level of M/XDR‑TB, RR, INH‑R, 
and FQ‑R isolates.[13]
Molecular studies on M. tuberculosis
M. tuberculosis Complex strains were identified by the 
commercial technique GenoTypeCM Mycobacterium 
Assay™ (GT‑CM).[14]
For MDR‑TB detection, it was used the GenoType 
MTBDRPlus™ (GTTBMDR) system which simultaneously 
identifies mutations in inhA and katG genes related to INH‑R, 
and mutations located in the “hot spot region” of rpoB gene 
associated to RR.[14,15]
DNA sequencing for detecting mutations related to RR, INH‑R, 
and FQ‑R was also performed as previously published.[15] 
Briefly, isolates INH‑R was investigated by sequencing a 
segment of 435 bp of katG gene, another of 648 bp of inhA 
promoter region and the whole inhA gene. A segment of 250 bp 
of rpoB gene was also sequenced searching mutations related 
to RR. The 320 bp of the “Quinolone resistant determining 
region” in the gyrA and the 375 bp in gyrB were also sequenced 
looking for mutations related to FQ‑R.[16‑18]
Two molecular genotyping methods used to determine genetic 
diversity of the M. tuberculosis strains were used in sequential 
steps: (a) the spacer oligonucleotide typing or spoligotyping, 
which is based on a polymerase chain reaction amplification 
of the clustered regularly interspaced short palindromic repeats 
locus and detection of the presence of different spacers between 
the repeats by reverse hybridization on a membrane; (b) 
genetic patterns analysis obtained by restriction fragment 
length polymorphism (RFLP) using the insertion sequence 
6110 (IS6110) as probe (IS6110‑RFLP).[19,20]
Statistical analysis
Epidemiological, clinical, and microbiological data were 
collected in an Excel file designed to collect the involved 
variables. The Microsoft MedCalc 16.4 (MedCalc Software, 
Mariakerke, Belgium) was used to analyze results.[12,15]
The analysis of the molecular patterns of the isolates was 
performed by the BioNumerics™ software (Applied Maths 
NV, Sint‑Marten‑Latem, Belgium) while octal codes obtained 
by spoligotyping were determined and compared using 
the international database, SITVITWEB (http://www. 
pasteur‑guadeloupe. fr: 8081/SITVIT_ONLINE/contact. jsp).[21‑23]
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results
Mycobacterial isolates
During the study, mycobacteria as etiological agents of the 
disease were isolated from 3,014 patients: 2758 (91.5%) were 
confirmed as TB, and in 256 (8.5%) cases, a nontuberculous 
mycobacteria (NTM) was considered the pathogenic agent. 
Men accounted for 61.0% of the whole cases. The global HIV 
coinfection reached 6.1% (n: 184) of the cases, 149 (5.4%) in 
TB, and 19 (7.4%) in NTM‑infected individuals; 407 (13.5%) 
cases had an extrapulmonary localization of the disease and 
347 (11.5%) were isolates submitted to the laboratory for 
identification and/or DST. A total of 2206 (80.0%) TB cases 
had pulmonary localization of the disease and 1482 (67.2%) 
with acid‑fast bacilli demonstrable by Ziehl–Neelsen stain. 
Besides, the sanitary system identified 822 (29.8%) as 
previously treated cases.
A total of 1582 M. tuberculosis isolates, 427 (27%) from 
previously treated cases, were processed by DST and 
722 (45.6%), suspected of being M/XDR‑TB, were selected 
to be studied by molecular methods.
Drug susceptibility testing
Phenotypic DST results are shown in Table 1. During the study, 
a total of 340 (21.5%) out of 1582 cases with DST results had 
a disease caused by an isolate resistant to at least one anti‑TB 
agent (DR‑TB): 96 (28.2%) were globally RR, 18 (5.3%) of 
them mono RR; 166 (48.8%) were globally INH‑R while 
M/XDR plus Pre‑XDR accounted for 78 (22.9%) of the tested 
organisms.
Global DR was found in 90 out of 427 (21.8%) previously 
treated patients being RR‑TB detected in 38 (8.9%) and 
58 cases out of 1155 (5.0%) with and without treatment 
background, respectively.
Regarding the global incidence calculated on the 1582 
individuals tested, RR and INH‑R accounted for 6.1% and 
10.5%, respectively, while M/XDR‑TB and Pre‑XDR‑TB 
occurred in 4.9% of the cases.
Resistance to aminoglycosides (amikacin and/or kanamycin) 
was found in 9 cases, 7 with a Pre‑XDR‑TB pattern while 
FQs (levofloxacin and moxifloxacin) resistance was verified 
in 2x DR‑TB and 2 Pre‑XDR cases.
Molecular drug resistance
Genotypic valid results were obtained for 760 out of 
772 (98.4%) analyzed isolates. A total of 236 genomic analyses 
of the rpoB, katG, inhA, and gyrA/gyrB genes were performed 
on 186 out of the 193 (96.4%) phenotypically characterized 
DR cases. Only those isolates showing also resistance to 
aminoglycosides were not molecularly investigated.
Table 2 shows mutations or deletions related to RR and INH‑R. 
The comparison of GTTBMDR results and sequencing is also 
shown in Table 2. The overall concordance for RR and INH‑R 
detection between the two methods was 97.0%.
RR was detected in 77 isolates simultaneously by GTTBMDR 
and sequencing and 13 (16.9%) showed discordant results. In 
6 (8%) RR cases, a wild type GTTBMDR was found while 
sequencing revealed 1: case with deletion at codon position 537 
of the rpoB gene, 3 (4.0%) with a point mutation ATG > ACG 
at codon 515, 1 mutated at codon 531, and 1 mutated at position 
572 (ATC>TTC), [Table 2].
The followings were the rest of discrepancies found: 1 strain 
presented a TCG531TTG mutation detected by GTTBMDR 
while sequencing showed GAC516GTC mutation; 3 strains 
mutated at GAC517GGC by GTTBMDR showed by 
sequencing a deletion affecting codons 510–517 of rpoB gene; 
in 3 strains, GTTBMDR detected a CAC526TAC mutation but 
sequencing showed 2 strains with CAA513CCA and 1 with 
GAC565CAG mutations [Table 2]. Besides, in one case, a 
multiple mutation comprising codons 513–566 were found.
INH‑R was correctly detected by GTTBMDR in fully 
agreement with sequencing in 95.5% (150/157) of the tested 
isolates. In 5 (3.2%) cases, the GTTBMDR gave wild type 
patterns for inhA promoter region and katG gene, but mutations 
at codons 321, 107, 315 and the open reading frame of the inhA 
gene were detected by sequencing [Table 2].
Analyzing the discrepancies found in detecting mutations 
leading to RR and INH‑R by GTTBMDR and sequencing 
considered as the gold standard, the agreement between both 
methods was 91.5% (214/234).
Relations between mutations and DR levels reveal that 118 
out of 125 (94.4%) of INH‑R strains mutated in katG gene 
had INH MIC values ranged between 16.0 and ≥32.0 µg/mL 
while 75.0% (24/32) of the inhA mutated strains presented 
MIC values between 1.0 and 0.50 µg/mL. Almost 90% of 
the RR strains showed resistance levels ranged from 8.0 
to ≥64.0 µg/mL regardless the rpoB mutation. Both FQ‑R 
Table 1: Predominant drug‑resistance patterns found by 
phenotypic drug‑susceptibility testing methods
Year Patient n° (%)
DST/Pt DRt RRt INHt MDR P‑XDR XDR
2017 345 200 45 14 22 11 1
2016 335 191 43 10 22 8 ‑
2015 265 160 46 13 26 8 3
2014 327 183 40 13 19 11 1 1
2013 387 210 44 14 24 12 1
2012 337 202 38 12 14 5 1
2011 375 217 47 13 26 9 ‑ 1
2010 387 219 37 7 13 5 ‑
Total n° 2758 1582 340 96 166 69 7 2
Percentage 100 57.4 21.5 6.1 10.5 4.9
DST/Pt: Drug‑susceptibility testing per patient, t: Total figures, 
DRt: Total drug resistance, RRt: Total resistance to RIF, INHt: Total 
resistance to INH, MDR: Strain resistant simultaneously at least to INH 
and RIF, P‑XDR: Multidrug‑resistant strain also resistant to either an 
aminoglycoside tested (capreomycin, kanamycin, or amikacin) or a 
fluoroquinolone (levofloxacin [LX], ofloxacin, and moxifloxacin), XDR: 
TB caused by a strain resistant also to isoniazid and rifampicin
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strains mutated at gyrA GAC94TAC (D > Y) showed 
MIC ≥16.0 µg/mL.
Genotyping
Table 2 also shows the predominant spoligotyping 
families – expressed in percentages of the total patterns 
found for each one of the strains – in which the DR isolates 
could be grouped. Latin‑American and Mediterranean family, 
T (Tuscany), and H (Haarlem) lineages were the more 
representative ones.
In one patient with a first drug‑susceptible isolate, genetic 
patterns allowed the confirmation of MDR generation in the 
original strain discarding the reinfection from an external 
contagious source. Spoligotyping was also used to analyze seven 
isolates from health‑care workers from two different hospitals.
Three cases showed an infrequent deletion in rpoB gene with 
GAA base‑sequence located between 2 contiguous codons: G, 
last base of 517, and AA 2 first bases of codon 518. Two of 
these isolates showed identical spoligotyping pattern.
Table 2: Mutations of drug‑resistant strains found by GenoType MTBDRPlus and DNA sequencing related to the 
predominant spoligotyping patterns family
Gene position GenoType MTBDRPlus Sequencing Spoligotyping
n° Sequence mutation aa changed n° Sequence mutation aa changed Family Percentage
rpoB (N: 77)
531 45 TCG531TTG Ser>Leu 44
1
TCG531TTG
GAC516GTC
Ser>Leu
Asp>Val
LAM3, 5, 9
T1
H2
OP
48.3
24.1
13.8
‑
531 1 TCG531CCG Ser>Pro 1 TCG531TTG Ser>Leu T 1/1
516 4 GAC516GTC Asp>Val 4 GAC516GTC Asp>Val T 3/4
526 8 CAC526TAC His>Tyr 8 CAC526TAC His>Tyr T 8/8
526 2 CAC526TAC His>Tyr 2 CAA513CCA/
GAC565CAG
Gln>Pro/
Asp/Gln
T5 2/2
526 1 CAC526TAC Gln>Tyr 1 CAA513CCA Gln>Pro T 1/1
526 1 CAC526GAC His>Asp 1 CAC526GAC His>Asp
2 CAC526GAC His>Asp 2 CAC526CTC His>Leu U 2/2
522
522
1
2
TCG522TTG
TCG522CAG
Ser>Leu
Ser>Gln
1
2
TCG522CAG
TCG522CAG
Ser>Gln
Ser>Gln
T 3/3
516 3 GAC517GGC ‑ 3 DEL 510‑517 ‑ T1
LAM3
2/3
1/3
1 Not defined 1 Multiple mutations*** LAM5 1/1
WT 1 ‑ ‑ 1 TCG531TTG Ser>Leu ND ‑
WT 1 ‑ ‑ 1 DEL537 ‑ LAM 1/1
WT 3 ‑ ‑ 3 ATG515ACG Met>Thr T5 3/3
WT 1 1 ATC572TTC Ile>Phe H3 1/1
KatG (N: 125)
315 119 AGC315AAC Ser>Thr 119 AGC315AAC Ser>Thr LAM3, 5, 9
H2
T
19.8
2.8
7.5
WT 1 ‑ ‑ 1 TGG321TGC Trp>Cys T1 1/1
WT 1 ‑ ‑ 1 AAA107AAA Lys>Lys LAM3 1/1
315 2 AGC315AAC Ser>Thr 1
1
ATC321ACC
ATC317ACC
Lys>Asn
Ile>Thr
ND
ND
‑
‑
WT 2 ‑ ‑ 2 AGC315AGA Lys>Arg LAM3
H2
1/1
1/1
InhA (N: 32)
‑15 29 C‑15T 28
1
C‑15T
C‑17
H3
LAM3, 9
T1
Beijing
T1
18.8
21.9
28.1
3.1
1/1
2 C‑8T 2 C‑8T LAM9 2/2
1 WT 1 GGG83AGG Gly>Arg LAM9 1/1
Total 234
***Mutations at positions: 542, 544, 548, 550, 552, 562, 566 of the rpoB gene; OP: Orphan pattern, WT: Wild type, aa: Amino acid
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Geographical distribution of the resistant isolates revealed 
isolates carrying mutations in the promoter region of the inhA 
gene that were exclusively found and constrained to three 
neighborhoods districts of the NSRBA region, where it was 
also registered two cases, in the same family relatives, with 
the infrequent rpoB S522 L/Q mutation.
dIscussIon
Among the whole landscape of TB worldwide, Argentina 
is considered as a middle TB incidence country. However, 
according to the last national epidemiological report released 
in 2018, since 2013, the trends are showing an increment in 
the total amount of cases. This increment was particularly 
produced between the years 2017 and 2018.[7,24]
This study has shown a DR‑TB prevalence of approximately 
20% of the circulating M. tuberculosis strains and an incidence 
of M/XDR‑TB, and particularly RR affecting more than 
5.0% of the total amount of cases registered in CH during the 
study. Regarding the global incidence calculated on the 1582 
individuals tested, RR‑TB and INH‑R accounted for 6.1% 
and 10.5%, respectively, while M/XDR‑TB and Pre‑XDR‑TB 
occurred in 4.9% of the cases. These results focus on a higher 
risk of being infected by a DR‑TB when residing in NSRBA 
area.
On the other hand and according with the obtained results, 
it would be convenient to confirm by phenotypic methods, 
the susceptibility to INH and RIF detected by commercial 
tests especially in highly DR‑TB suspected individuals. 
This concept is based on discordances found in some of the 
isolates between phenotypic and molecular methods on DR 
detection, elucidated later by gene sequencing.[16,25] Besides, 
the knowledge of DR levels related to the mutated codons 
leading to INH and RIF resistance could help to orientate the 
treatment particularly in the replacement of INH‑structural 
analog, ethionamide instead of INH, in those INH‑R isolates 
carrying katG and no inhA mutation.[26]
A practical subproduct of this work was obtained by analyzing 
the spoligotyping patterns from 2 supposed nosocomial 
outbreaks apparently occurred during the year 2016 among the 
health‑care workers staffs from two different hospitals. The 
prime idea of being nosocomial outbreaks could be discarded 
on the basis of the different orphan spoligotyping patterns 
found. This fact shows no connection among the involved 
people.
As it was previously observed and reported, the genotyping 
analysis of DR isolates can contribute to surveillance activities 
on the clonal dispersion of the community transmission of 
the main lineages. This surveillance can help to estimate the 
proportions of endogenous reactivation and active transmission 
of DR strains in the community.[27] The fact that most DR/
MDR‑TB isolates were not grouped in genetic clusters suggests 
that these cases may mostly have occurred due to endogenous 
reactivation than for recent transmission.[27,28]
Geographical distribution of the DR isolates revealed mutations 
in the promoter region of the inhA gene circulating so far in 
three neighborhoods districts of the NSRBA. At the same time 
and in the same region, two cases from family relatives with 
the infrequent rpoBS522 L/Q mutation were also registered. An 
exhaustive contact tracing of these cases, as well as prevention 
measures, should be maintained over the time to prevent the 
spreading of these strains in the community.
conclusIons
Results of this study also emphasized the need of a properly 
detection of DR cases. Implementing DST to all new 
diagnosed cases as well as those previously treated. Resources 
to accomplish with this WHO recommendation should be a 
priority.
On the other hand, the development and standardization of 
DST methodology to second‑line and alternative anti‑TB 
compounds (e.g., clofazimine, linezolid, and new generation 
FQs) are urgently needed to monitor the emergence of 
resistance and should be a higher priority when such a new 
drugs are introduced.[29]
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